Stayble Therapeutics AB (DE:4K4)
FRANKFURT:4K4
4K4 Stock Chart & Stats
€0.02
>-€0.01(-2.27%)
At close: 4:00 PM EST
€0.02
>-€0.01(-2.27%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.19M
Enterprise Value€10.61M
Total Cash (Recent Filing)€2.45M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.16
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding64,359,795
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.92
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Loss And Cash Burn TrendEBIT and cash burn have improved materially (EBIT narrowed from ~-24.8M in 2022 to -6.9M in 2025 and operating cash burn from -24.0M in 2020 to -6.7M in 2025). This durable trend reduces near-term financing pressure, extending runway to reach clinical value inflection points.
Low Financial LeverageA debt-free balance sheet in 2025 means limited fixed financial obligations and greater flexibility to raise capital on favorable terms or prioritize R&D spend. Low leverage supports strategic options without immediate pressure from interest or covenant constraints.
Focused, Differentiated Clinical ProgramA concentrated pipeline centered on STA363, which targets underlying degenerative disc pathology rather than only symptoms, gives a clear product-market fit and potential clinical differentiation. This focus can streamline development, regulatory strategy, and commercial positioning long term.
Bears Say
Pre-revenue Business ModelThe company remains pre-revenue with no reported sales from 2020–2025, meaning it cannot self-fund operations. Long-term viability depends on successful clinical outcomes and external financing, increasing execution and funding risk before commercialization can generate cash.
Eroding Equity BaseA sharply reduced equity base reflects accumulated losses and likely dilution. This weakens the capital buffer available for setbacks, elevates the probability of future capital raises, and can dilute existing shareholders, impacting long-term investor returns and strategic flexibility.
Persistent Negative Cash Flow And Liquidity RiskOperating cash flow remains negative despite improvement, and free cash flow is generally negative. The business still requires external funding to progress clinical programs. Timing and availability of financing create structural execution risk over the coming months.
4K4 FAQ
What was Stayble Therapeutics AB’s price range in the past 12 months?
Stayble Therapeutics AB lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is Stayble Therapeutics AB’s market cap?
Stayble Therapeutics AB’s market cap is €1.19M.
When is Stayble Therapeutics AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Stayble Therapeutics AB’s earnings last quarter?
Currently, no data Available
Is Stayble Therapeutics AB overvalued?
According to Wall Street analysts Stayble Therapeutics AB’s price is currently Overvalued.
Does Stayble Therapeutics AB pay dividends?
Stayble Therapeutics AB does not currently pay dividends.
What is Stayble Therapeutics AB’s EPS estimate?
Stayble Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Stayble Therapeutics AB have?
Stayble Therapeutics AB has 64,359,795 shares outstanding.
What happened to Stayble Therapeutics AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Stayble Therapeutics AB?
Currently, no hedge funds are holding shares in DE:4K4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Stayble Therapeutics AB
Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.